Johnson & Johnson Recalling 9.3 Million Bottles of Tylenol Products

Updated
Johnson & Johnson Tylenol
Johnson & Johnson Tylenol

Johnson & Johnson (JNJ) is recalling nearly 9.3 million bottles of of three Tylenol Cold Multi-Symptom liquid products in order to update the product labeling.

The pharmaceutical giant's McNeil Consumer Healthcare unit said the recalled products don't mention they contain a small amount of alcohol from the flavoring agents on the front label. Certain flavoring agents, it explains, contribute small amounts of alcohol, less than 1%, to the medicine. The alcohol is listed as inactive ingredients on the back of the packaging and on the bottles.

While this is a wholesale and retail level recall, it is not due to adverse events, the company said. Consumers can continue to use the products.

The affected products, which are sold in the U.S., are: Tylenol Cold Multi-Symptom Daytime 8 Oz Citrus Burst Liquid, Tylenol Cold Multi-Symptom Severe 8 Oz Cool Burst Liquid, and Tylenol Cold Multi-Symptom Nighttime 8 Oz Cool Burst Liquid.

Sponsored Links

Johnson & Johnson has been conducting a complete review of its products following massive recalls of popular over-the-counter medicines over the past year. More than 135 million bottles of over 40 of its children's medicines were recalled in late April because of manufacturing deficiencies, after which the company suspended manufacturing at its plant in Fort Washington, Pa.

Just on Tuesday, the health care giant recalled about 4 million packages of Children's Benadryl allergy tablets and some 800,000 bottles of Junior Strength Motrin, after manufacturing problems were revealed in the internal review. As the review goes on, there may be more recalls, even though the company just started shipping some of the long-absent products again.

Johnson & Johnson's financial results have suffered from the recalls as lost sales mounted. But it's not enough to start selling products again, consumers have to buy them. And to get the public's trust again, Johnson & Johnson needs to get its act together.

Advertisement